Medicine
Antiphospholipid Syndrome: Diagnostic Criteria and Anticoagulation Strategies
Quick fact
Antiphospholipid syndrome is a leading cause of recurrent miscarriage and premature clotting—it can cause blood clots in any vessel, leading to strokes, heart attacks, and pulmonary emboli, even in young people.
Why this is interesting
Imagine your immune system, which should protect you, mistakenly attacking your own blood vessels and causing life-threatening clots. That's what happens in antiphospholipid syndrome—a disease where the body creates antibodies that turn your blood into a clotting hazard.
Read the full explanation
Understanding Antiphospholipid Syndrome: Diagnostic Criteria and Anticoagulation Strategies
Antiphospholipid syndrome (APS) is an autoimmune condition where the immune system produces antibodies (antiphospholipid antibodies) that mistakenly target proteins that bind to phospholipids on cell membranes. These antibodies are not mere bystanders; they directly increase the risk of blood clots (thrombosis) and certain pregnancy complications. The diagnosis is based on a combination of clinical features (at least one episode of blood clot or specific pregnancy morbidity) and laboratory findings (the presence of antiphospholipid antibodies on two or more occasions at least 12 weeks apart). The most commonly tested antibodies are lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-beta-2-glycoprotein I (aβ2GPI). The diagnosis also requires that the laboratory tests be positive persistently, not just at a single point, to avoid false positives from infections or medications. This combination of clinical and serologic criteria forms the basis of the updated Sapporo/Sydney criteria. The management of APS focuses on preventing further clotting. For individuals with a history of thrombosis, long-term anticoagulation is recommended. Usually, this means taking a vitamin K antagonist like warfarin to maintain an international normalized ratio (INR) of 2-3. For pregnant women with APS and a history of thrombosis, anticoagulation is continued, often with low-molecular-weight heparin and low-dose aspirin. For those with only pregnancy morbidity, aspirin and heparin are used. The goal is to reduce the high risk of recurrent clots and improve pregnancy outcomes.
A deeper explanation
The mechanisms by which antiphospholipid antibodies cause thrombosis are complex but involve multiple pathways. These antibodies can bind to endothelial cells, platelets, and monocytes, activating them and increasing the expression of tissue factor, which initiates the coagulation cascade. They can also interfere with natural anticoagulant proteins, such as protein C and protein S, and disrupt the annexin A5 shield—an anticoagulant phospholipid-binding protein that normally covers exposed phospholipids on cell surfaces, thereby hampering the assembly of coagulation factors. When these antibodies bind, the shield is disrupted, exposing phospholipids and promoting clot formation. Additionally, complement activation and increased neutrophil extracellular traps (NETs) contribute to a prothrombotic state. The laboratory detection of lupus anticoagulant relies on the ability of these antibodies to prolong phospholipid-dependent clotting tests (e.g., activated partial thromboplastin time, dilute Russell's viper venom time)—paradoxically because the antibodies bind to phospholipids and impede the clotting reaction in vitro, but in vivo they promote thrombosis. Treatment strategies hinge on this prothrombotic state. Warfarin, a vitamin K antagonist, is the mainstay for secondary prevention of thrombosis because it effectively reduces the risk of recurrent clots. Direct oral anticoagulants (DOACs) like rivaroxaban are generally not recommended for APS, especially for those with triple positivity (LA, aCL, aβ2GPI), because they may be less effective and have a higher risk of recurrent thrombosis. For patients with catastrophic APS, a severe accelerated form, aggressive treatment with anticoagulation, corticosteroids, plasma exchange, and rituximab may be necessary. Understanding these mechanisms and the rationale behind anticoagulation strategies is crucial for clinicians to manage patients and prevent life-threatening events.